Alpha-Lipoic Acid Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Alpha-Lipoic Acid dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Alpha-Lipoic Acid.
Dosing Protocols
BEGINNER PROTOCOL (GENERAL ANTIOXIDANT SUPPORT OR EARLY METABOLIC SYNDROME). Start with 300 mg racemic ALA (or 100-200 mg R-ALA) once daily, taken on an empty stomach in the morning. If well-tolerated, increase to 600 mg racemic (or 300 mg R-ALA) after 1-2 weeks. Pair with biotin 2-5 mg daily to prevent SMVT-mediated competition, and ideally with vitamin C 500-1000 mg and CoQ10 100 mg as antioxidant recycling partners. Take levothyroxine (if applicable) at least 4 hours apart from ALA. Monitor for GI side effects (nausea, heartburn) and dial back if persistent. Expected effects: improvements in general oxidative stress markers, modest insulin sensitivity improvement over 4-8 weeks, subjective energy and cognitive clarity improvements reported by some users. Cost: $15-25/month for racemic; $25-50/month for R-ALA.
INTERMEDIATE PROTOCOL (DIABETIC NEUROPATHY OR CLINICAL INSULIN RESISTANCE). Oral ALA 600 mg twice daily (1200 mg total) OR 600 mg once daily of R-ALA, taken on empty stomach, separated from meals by at least 1-2 hours. Combine with alpha-lipoic acid's complementary partners: NAC 600 mg BID, vitamin C 1000 mg daily, biotin 5 mg daily, CoQ10 200 mg, magnesium 400 mg, B12 (methylcobalamin) 1000 mcg, omega-3 2 g EPA+DHA. For diabetic neuropathy specifically, add acetyl-L-carnitine 1000 mg twice daily. For type 2 diabetes or metabolic syndrome, consider co-administration with berberine 500 mg 2-3x daily for synergistic AMPK activation. Monitor blood glucose more frequently during first 2-4 weeks (hypoglycemia risk if on insulin/sulfonylureas), liver enzymes (AST/ALT) every 3-6 months, HbA1c and fasting insulin at 3 and 6 months to quantify insulin sensitivity improvement. Expected timeline: neuropathy symptom reduction over 3-5 weeks, HbA1c reduction of 0.2-0.4% over 3-6 months, meaningful TSS reduction in diabetic neuropathy. Cost: $30-60/month.
ADVANCED PROTOCOL (SEVERE NEUROPATHY / MITOCHONDRIAL SUPPORT / SUPERVISED CHELATION). For severe symptomatic diabetic neuropathy: initiate with IV ALA 600 mg daily for 10-14 days if accessible through functional medicine clinic, followed by oral 600 mg twice daily indefinitely, combined with ALCAR 1000 mg BID, methyl-B12 1000 mcg SL daily, benfotiamine 300 mg daily, and comprehensive diabetes management. For primary mitochondrial disease (MELAS, Leigh, CPEO): R-ALA 300-600 mg daily as part of mitochondrial cocktail including CoQ10 400-1200 mg, L-carnitine 2-3 g, creatine 5-10 g, riboflavin 100-400 mg, thiamine 100-300 mg — all under metabolic genetics supervision. For Cutler-style mercury chelation: requires extensive prerequisite study of the full protocol, typically 3-day rounds of ALA 25-100 mg every 3-4 hours around the clock combined with DMSA, with 3-day breaks between rounds, continued for months to years; working with a clinician experienced in heavy metal protocols is strongly recommended; this is NOT a casual supplementation approach. For long-term high-dose use, biotin 5-10 mg/day is mandatory; check MCV, lipid panel, liver enzymes, and complete metabolic panel every 3-6 months. Cost: varies widely, $50-150+/month for protocol ingredients plus clinician oversight costs.
Commonly Stacked With
Alpha-lipoic acid is a natural stacking partner for other antioxidants (because of its redox-regenerating role) and for insulin-sensitizing agents. The key principles are to complement rather than duplicate ALA's functions, to leverage its ability to recycle other antioxidants, and to respect its absorption quirks.
ALA + GLUTATHIONE SUPPORT (NAC, GLYCINE, GLUTAMINE). Glutathione is the dominant intracellular antioxidant and a major target of DHLA-mediated regeneration. Pairing ALA with the glutathione substrate chain — NAC for cysteine, glycine for glutathione synthase substrate, and glutamine for γ-glutamyl-cysteine formation — creates a reinforcing antioxidant ecosystem. Typical stacking: ALA 600 mg + NAC 600-1200 mg + glycine 3-5 g daily. This combination is particularly useful for liver support (NAFLD, hepatic oxidative stress), heavy metal exposure, and general antioxidant optimization. See /compound/glutathione, /compound/nac, /compound/glycine.
ALA + VITAMIN C. DHLA directly regenerates dehydroascorbate (oxidized vitamin C) back to ascorbate, closing a cycle where vitamin C delivers electrons to oxidants and ALA returns vitamin C to its reduced form. This pairing is chemically rational and practically effective. Vitamin C 500-2000 mg daily + ALA 600 mg daily is a standard antioxidant stack. See /compound/vitamin-c.
ALA + VITAMIN E. DHLA indirectly regenerates tocopheroxyl radical back to α-tocopherol via the ascorbate cycle. Vitamin E sits at the lipid-membrane frontier while ALA/DHLA works across both aqueous and lipid phases. The combination is particularly relevant for diabetic complications (where both polyunsaturated fatty acid peroxidation and water-soluble oxidants cause damage) and NAFLD. Mixed tocopherols 100-400 IU daily + ALA 600 mg is typical.
ALA + COQ10. DHLA can reduce ubiquinone to ubiquinol, restoring CoQ10's antioxidant and electron-transport functions. This stack is the mitochondrial support standard: ALA 300-600 mg + CoQ10 100-200 mg daily, often with L-carnitine 1-2 g daily. Particularly relevant for mitochondrial disorders, statin-associated myopathy, and cardiovascular support. See /compound/coq10.
ALA + BIOTIN (MANDATORY FOR CHRONIC HIGH-DOSE ALA). Because ALA competitively inhibits biotin uptake through shared SMVT transporter, chronic ALA ≥600 mg/day induces functional biotin deficiency over months. Biotin 2-5 mg/day prevents this. Many commercial R-ALA products include biotin for this reason. This is not optional for long-term high-dose users.
ALA + METFORMIN (SYNERGY FOR INSULIN RESISTANCE). Metformin and ALA have complementary mechanisms for insulin sensitization: metformin activates AMPK via LKB1 and reduces hepatic glucose production; ALA activates AMPK independently, enhances GLUT4 translocation, and provides antioxidant protection for insulin signaling machinery. The combination is commonly used in type 2 diabetes and metabolic syndrome, with ALA providing neuropathy protection that metformin does not. Note: metformin users should supplement B12 (see /compound/vitamin-b12) because metformin reduces B12 absorption.
ALA + BERBERINE. Berberine activates AMPK through mechanisms overlapping with metformin and has insulin-sensitizing, lipid-modifying, and glucose-lowering effects. Combining ALA 600 mg + berberine 500 mg twice daily provides complementary mechanisms for metabolic syndrome and PCOS. See /compound/berberine.
ALA + L-CARNITINE / ACETYL-L-CARNITINE. Acetyl-L-carnitine (ALCAR) supports mitochondrial fatty acid oxidation and has independent evidence for diabetic neuropathy. Pairing ALCAR 1-2 g with ALA 600 mg provides dual neuropathy protection and is a common combination for diabetic peripheral neuropathy.
ALA + CHROMIUM / MAGNESIUM / ZINC. Chromium picolinate, magnesium, and zinc all support insulin signaling through distinct mechanisms. Including these in an insulin-sensitizing stack (e.g., ALA 600 mg + chromium 200 mcg + magnesium 400 mg + zinc 15-25 mg daily) provides a comprehensive micronutrient-based approach to insulin resistance. See /compound/magnesium and /compound/zinc.
ALA + OMEGA-3. Omega-3 fatty acids reduce systemic inflammation and triglycerides but are vulnerable to lipid peroxidation in storage and in vivo. ALA's antioxidant protection of polyunsaturated fatty acid membranes is particularly valuable when taking high-dose omega-3. Typical pairing: fish oil 2-3 g EPA+DHA + ALA 600 mg daily. See /compound/omega-3-fatty-acids.
ALA + THYROID HORMONE (TIMING CAUTION). ALA can modestly interfere with levothyroxine absorption if taken simultaneously. Separate doses by ≥4 hours; take levothyroxine in the morning fasted and ALA with lunch or dinner.
ALA AND INSULIN/SULFONYLUREAS (MONITORING REQUIRED). Diabetics on insulin or sulfonylureas adding ALA should monitor glucose more frequently for the first 2-4 weeks and anticipate possible insulin or sulfonylurea dose reduction if recurrent hypoglycemia develops.
ALA + DMSA (CHELATION STACK). Cutler-style protocols combine ALA with DMSA for mercury chelation, exploiting different distributions: DMSA handles extracellular/blood mercury while ALA's tissue penetration addresses intracellular pools. These protocols require precise dosing schedules and experienced supervision.
AVOID ALA + DIRECT OXIDANT CHEMOTHERAPY AND RADIATION (RELATIVE). Theoretical concern exists that antioxidants may reduce the efficacy of chemotherapy agents that kill cancer cells via oxidative damage (cisplatin, carboplatin, doxorubicin) or radiation therapy. Clinical evidence is mixed and some studies suggest ALA is neutral or protective only of healthy tissue. Patients on active chemotherapy or radiation should discuss ALA use with their oncologist rather than self-supplementing.
EMPTY STOMACH ADMINISTRATION. ALA is best absorbed when taken on empty stomach (1 hour before or 2 hours after meals), which maximizes bioavailability by about 30-50% compared to taking with food. Morning or bedtime dosing is often most practical.
CAFFEINE AND ALCOHOL. No direct interactions documented. Heavy alcohol use may exacerbate ALA-induced GI symptoms and alcoholic neuropathy may benefit from ALA via similar mechanisms as diabetic neuropathy.
Side Effects & Safety
Contraindications
Alpha-lipoic acid is well-tolerated for most users at standard doses, but several clinical scenarios warrant caution, dose modification, or avoidance. DIABETES WITH INSULIN OR SULFONYLUREA THERAPY (USE WITH MONITORING). The most important clinical interaction: ALA has insulin-sensitizing effects that can precipitate hypoglycemia in patients on insulin, sulfonylureas (glipizide, glyburide, glimepiride), or meglitinides (repaglinide, nateglinide). This is NOT a contraindication but requires more frequent blood glucose monitoring during the first 2-4 weeks of ALA initiation, and insulin or sulfonylurea doses may need to be reduced (often by 10-20%) to prevent symptomatic hypoglycemia. Discuss with prescribing clinician before starting ALA if on these medications. INSULIN AUTOIMMUNE SYNDROME (HIRATA DISEASE) RISK. Asian populations, particularly Japanese and Korean with HLA-DRB1*04:06 haplotype, have documented risk of developing insulin autoimmune syndrome triggered by ALA. This rare condition produces spontaneous hypoglycemia due to anti-insulin antibodies and typically resolves weeks to months after ALA discontinuation. Users of Asian ancestry should be aware; consider avoiding chronic high-dose ALA if family history of autoimmune conditions. This risk is substantially lower in Caucasian and other populations due to HLA distribution differences. PREGNANCY. Avoid ALA supplementation during pregnancy unless specifically indicated by a clinician managing a high-risk condition; safety data in pregnancy is insufficient, and ALA is not a standard pregnancy supplement. The theoretical antioxidant benefit is outweighed by uncertainty. LACTATION. Limited data on ALA in breast milk; standard recommendation is to avoid during breastfeeding or to consult with clinician if specifically indicated. PEDIATRIC USE. ALA has limited safety data in children. Use should be reserved for specific medical indications (e.g., primary mitochondrial disease) under pediatric metabolic genetics supervision. Routine supplementation in healthy children is not appropriate. THIAMINE (B1) DEFICIENCY. Severe thiamine deficiency (classical beriberi, Wernicke-Korsakoff syndrome, severe alcoholism) should be corrected with parenteral thiamine before initiating ALA. ALA activates thiamine-dependent enzymes (pyruvate dehydrogenase, α-ketoglutarate dehydrogenase), and in thiamine-depleted tissues this can exacerbate the clinical manifestations of thiamine deficiency before repletion. ACTIVE CHEMOTHERAPY OR RADIATION THERAPY. Theoretical concern: antioxidants may reduce efficacy of chemotherapy agents that work through oxidative damage (cisplatin, carboplatin, doxorubicin, taxanes) or ionizing radiation. Clinical evidence is mixed — some studies show ALA selectively protects healthy tissue without impairing tumor response, others suggest potential interference with treatment efficacy. Patients on active cancer treatment should discuss ALA with their oncology team rather than self-supplementing. Post-treatment use for prevention of chemotherapy-induced peripheral neuropathy is better supported. SEVERE HEPATIC IMPAIRMENT. While ALA is hepatoprotective in most studies (benefits in NAFLD, acetaminophen toxicity), severe decompensated cirrhosis warrants caution with any supplement. Monitor liver enzymes and avoid high doses in advanced hepatic dysfunction. ACUTE PORPHYRIA. Theoretical concern based on sulfur metabolism interactions; data are lacking but standard caution applies to users with porphyria. ALLERGIC REACTION. Rare but documented allergy to ALA warrants discontinuation and avoidance of all forms (oral and IV). Cross-reactivity with other disulfide-containing compounds is not established. SEVERE HYPOGLYCEMIA HISTORY. Patients with frequent severe hypoglycemic episodes (with or without awareness) should initiate ALA with close monitoring, particularly if on insulin or sulfonylureas. SEVERE GASTROINTESTINAL DISEASE. Active peptic ulcer disease, severe gastritis, or refractory GERD may be exacerbated by ALA's irritant effects on upper GI mucosa. Consider reduced doses (100-300 mg) or enteric-coated formulations, or avoid until GI symptoms are controlled. THIOL SENSITIVITY. Rare patients with sulfa allergy or sulfur-containing drug sensitivities may be more likely to experience adverse reactions; monitor closely or avoid if indicated. HEAVY ALCOHOL USE. Chronic heavy alcohol use damages thiamine status, B12 status, liver function, and neurological integrity; ALA may be beneficial in this context but should be part of a complete nutritional repletion program including thiamine, B12, folate, and other deficient nutrients. Avoid as monotherapy in heavy drinkers without broader nutritional support. SURGERY. Discontinue ALA 1-2 weeks before elective surgery due to potential hypoglycemic effects and theoretical interactions with anesthesia; resume post-operatively once stable. Patients on chronic ALA for diabetic neuropathy may continue through the perioperative period with glucose monitoring at the surgical team's discretion. DRUG INTERACTIONS OF NOTE. Besides insulin/sulfonylureas already mentioned: levothyroxine (separate by ≥4 hours due to reduced absorption), cisplatin and other oxidative chemotherapy (discuss with oncologist), warfarin (no significant interaction established but prudent to monitor INR when starting), thyroid hormone more generally (modest effects on T3/T4 conversion), and other insulin sensitizers like pioglitazone (additive glucose-lowering effect, monitor). DOSE ADJUSTMENT FOR KIDNEY DISEASE. Standard dosing is generally safe in mild-to-moderate chronic kidney disease. For advanced CKD (eGFR <30) or dialysis, consider starting at lower dose (100-300 mg) and monitoring for accumulation of metabolites and any unusual effects. ALA is partly eliminated by urinary excretion of sulfur-containing metabolites.
Additional Notes
Alpha-lipoic acid is sold over the counter in the US and most jurisdictions as oral capsules, tablets, and (less commonly) as compounded IV formulations. Commercially available products include racemic ALA (R:S 50:50 mixture), pure R-ALA, stabilized sodium R-lipoate (Na-R-ALA), and occasionally time-release formulations. Dose selection must consider indication, isomer choice, and absorption optimization.
DOSE BY INDICATION. General antioxidant and metabolic support: 300-600 mg racemic ALA or 100-300 mg R-ALA daily. Diabetic neuropathy (oral): 600 mg racemic daily (the ALADIN/NATHAN/SYDNEY dose) or 300-600 mg R-ALA; many clinicians use 600 mg twice daily for active neuropathy pain. Insulin resistance and metabolic syndrome: 600-1800 mg racemic daily in divided doses, or 300-900 mg R-ALA daily. NAFLD: 600-1200 mg racemic or 300-600 mg R-ALA daily. Burning mouth syndrome: 200-600 mg racemic daily. Weight loss adjunct: 1200-1800 mg racemic daily. Mercury chelation (Cutler protocol): 25-100 mg every 3-4 hours around the clock during active rounds. Intravenous ALA (diabetic neuropathy loading, acute oxidative injury, heavy metal emergencies): typically 600 mg in saline over 30-60 minutes, given daily for 10-21 day courses — available through some functional medicine clinics and specific hospital protocols.
ISOMER CHOICE. Racemic ALA is the cheapest and most widely available form; half the material is the biologically inactive S-enantiomer which may even competitively interfere with R-ALA effects. R-ALA (or R-(+)-lipoic acid) is the natural enantiomer with approximately 40% higher peak plasma concentrations and 2-3x higher AUC than equivalent total doses of racemic material. Stabilized Na-R-ALA (sodium R-lipoate) is a specially-formulated product with improved solubility and further enhanced bioavailability over free R-ALA. For cost-sensitive users, racemic is fine at higher doses; for purer pharmacology or for users with GI intolerance to high doses of racemic, R-ALA or Na-R-ALA at lower doses achieves similar effects. Typical conversion: 600 mg racemic ≈ 300 mg R-ALA ≈ 200-250 mg Na-R-ALA.
TIMING AND FOOD. ALA is best absorbed on empty stomach — take 30-60 minutes before meals or 2 hours after meals. Absorption is reduced by 30-50% when taken with food, particularly carbohydrate-rich meals. Some users experience GI upset on true empty stomach; a light snack (e.g., a small amount of protein) represents a compromise that preserves most absorption. Morning fasted dosing is optimal for most users; pre-workout dosing is also popular. Avoid bedtime dosing if it causes GI discomfort; for long-acting insulin sensitivity effects, doses can be split to morning and pre-lunch.
LEVOTHYROXINE INTERACTION. Separate ALA and levothyroxine by at least 4 hours. Take levothyroxine morning fasted; take ALA with lunch or late afternoon.
DURATION. For neuropathy, metabolic syndrome, and other chronic indications, ALA is taken indefinitely — there is no evidence of tolerance, and cessation generally reverses the benefits over weeks. For acute applications (stroke, chemotherapy-induced neuropathy prevention), shorter defined courses are appropriate. Long-term safety data spans 4 years in NATHAN 1 and decades in German clinical practice; no cumulative toxicity has been identified at standard doses.
BIOTIN REPLACEMENT (MANDATORY FOR CHRONIC HIGH-DOSE ALA). Users taking ALA ≥600 mg/day for more than 3 months should add biotin 2-5 mg/day to prevent SMVT-transporter competition-induced biotin deficiency. Many commercial ALA products include biotin for this reason; check labels.
UPPER LIMIT. No official upper limit has been established. Doses up to 1800 mg/day are well-tolerated in controlled trials; doses above 2400 mg/day are uncommon and provide no additional benefit for standard indications. Acute overdose is rare but has been associated with hypoglycemia and seizures at doses >6 g in case reports.
SPECIAL POPULATIONS. Pregnancy: avoid unless specifically indicated; safety not established. Lactation: limited data; standard recommendation is to avoid. Pediatric: reserve for specific mitochondrial or metabolic indications under specialist supervision. Elderly: standard adult doses are typically well-tolerated; start at 300 mg and titrate. Renal impairment: no specific dose adjustments, but monitor for accumulation of thiol metabolites. Hepatic impairment: monitor liver enzymes; avoid in severe hepatic failure.
LAB MONITORING FOR CHRONIC HIGH-DOSE USE. Baseline and every 6-12 months: complete blood count, comprehensive metabolic panel (including liver enzymes, kidney function, glucose), HbA1c (if diabetic or at risk), biotin status (if indicated), thyroid function (TSH, free T4). Monitor blood glucose more frequently during first 2-4 weeks of initiation in diabetics.
COST CONSIDERATIONS. Generic racemic ALA is inexpensive ($10-20/month at 600 mg/day). R-ALA is typically 2-3x more expensive at equivalent total dose but effective at half the dose, making net costs similar. Na-R-ALA (Geronova brand, BioTivia brand, others) costs more but may justify the premium for sensitive users. Compounded IV ALA through functional medicine clinics costs $50-150 per infusion.
Frequently Asked Questions
What is the recommended Alpha-Lipoic Acid dosage?
Dosage for Alpha-Lipoic Acid varies by protocol. Consult a qualified healthcare provider.
How often should I take Alpha-Lipoic Acid?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Alpha-Lipoic Acid need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Alpha-Lipoic Acid side effects?
Alpha-lipoic acid is generally well-tolerated at standard doses (300-600 mg/day), but the side-effect profile is not completely benign and deserves attention particularly for long-term high-dose use and for users with specific comorbidities. GASTROINTESTINAL. The most common side effects of oral ALA are gastrointestinal: nausea, heartburn, abdominal cramping, diarrhea, and occasional vomiting. These are more common at higher doses (1200-1800 mg/day) than at 300-600 mg/day, more common when taken with food (though this is somewhat counterintuitive — food reduces absorption but can reduce GI irritation), and typically diminish with continued use. Starting at 300 mg and titrating over 1-2 weeks reduces GI intolerance. Persistent nausea warrants dose reduction or discontinuation. HYPOGLYCEMIA. ALA has insulin-sensitizing effects that can precipitate hypoglycemia in diabetics taking insulin, sulfonylureas, or meglitinides. This is the most important clinical safety concern for supplemental ALA. Diabetics starting ALA should monitor blood glucose more frequently during the first 2-4 weeks, and insulin or sulfonylurea doses may need to be reduced to prevent symptomatic hypoglycemia. In non-diabetic users, clinically significant hypoglycemia is rare but has been reported, particularly with high doses on empty stomach in fasted or low-carbohydrate states. INSULIN AUTOIMMUNE SYNDROME (HIRATA DISEASE). ALA has been identified as a trigger for insulin autoimmune syndrome — a rare condition characterized by spontaneous hypoglycemia due to anti-insulin antibodies, most commonly reported in Japanese and Korean populations with specific HLA-DRB1*04:06 haplotype. Case reports since the mid-2000s have established ALA as the most frequent drug trigger for this condition in East Asia (Uchigata). Symptoms include recurrent episodes of hypoglycemia 2-4 hours after meals, often in previously healthy individuals. The condition typically resolves within weeks to months of ALA discontinuation. Asian users should be aware of this rare but well-documented adverse event; Western populations appear at much lower risk due to the HLA distribution. BIOTIN DEFICIENCY. Chronic high-dose ALA (≥600 mg/day for months) reduces biotin absorption through competition at the SMVT transporter, producing functional biotin deficiency with associated symptoms including hair thinning, brittle nails, dermatitis, and rarely more serious metabolic effects. Co-supplementation with biotin 2-5 mg/day prevents this and is standard practice in long-term ALA protocols. ALLERGIC REACTIONS AND SKIN RASH. Urticaria, pruritic rash, and in rare cases generalized dermatitis have been reported. Most reactions are mild and resolve with discontinuation. Severe hypersensitivity is uncommon. LIVER ENZYME ELEVATION. Transient mild elevations in AST and ALT have been reported in a small fraction of users, particularly at high doses. Clinically significant hepatotoxicity is rare but has been described in isolated cases. Monitor liver function periodically in users on chronic high-dose regimens (≥1200 mg/day for extended periods). THYROID EFFECTS. ALA can modestly alter thyroid hormone conversion, with some users reporting changes in TSH, T4, or T3 on chronic supplementation. Effects are generally small but may be relevant for patients on thyroid hormone replacement therapy, who should monitor thyroid function when starting or stopping ALA. DRUG INTERACTIONS. Beyond the insulin/sulfonylurea interaction already mentioned, ALA has modest interactions with thyroid hormone (may reduce levothyroxine absorption if taken simultaneously — separate by ≥4 hours), chemotherapy agents (theoretical concern that antioxidants may reduce efficacy of oxidative-damage-dependent agents like cisplatin or radiation, though clinical data is mixed), warfarin (no significant interaction in controlled studies), and alcohol (may worsen ALA-induced GI symptoms). METAL REDISTRIBUTION. In Cutler-style heavy metal chelation protocols, inappropriate dosing schedules can mobilize mercury from stable deposits at a rate exceeding urinary excretion capacity, potentially redistributing mercury into the CNS or other sensitive tissues. The short plasma half-life of ALA (30-60 minutes) requires frequent dosing (every 3-4 hours round-the-clock during active rounds) to maintain a steady chelation equilibrium and avoid mobilization-redistribution cycles. Users pursuing chelation should work with clinicians experienced in heavy metal protocols and consider DMSA as the first-line agent. SMELL AND BODY ODOR. Some users report a mild sulfurous or "eggy" body odor with high-dose ALA, reflecting the sulfur-containing metabolism. The effect is idiosyncratic, mild, and not reported by most users. PREGNANCY AND LACTATION. ALA has not been adequately studied in pregnancy or lactation; it should be avoided during pregnancy unless specifically indicated by a clinician. Limited data suggest some ALA appears in breast milk. The standard recommendation is to avoid ALA supplementation during pregnancy and breastfeeding. PEDIATRIC USE. ALA has limited safety data in children; use should be reserved for specific indications under clinical supervision (e.g., primary mitochondrial disorders in pediatric metabolic genetics). LONG-TERM SAFETY. The longest controlled safety data come from NATHAN 1 (4 years at 600 mg/day) with no major safety signals. Longer-term experience in clinical practice in Germany spans decades with a clean safety profile at 300-600 mg/day. Very long-term use at doses above 1200 mg/day is not well-characterized.
Where can I buy Alpha-Lipoic Acid?
Visit our vendor directory to find trusted sources for Alpha-Lipoic Acid.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
